SONO - SONO

옵션 체인은 다양한 행사가격과 만기일에 대한 Sonos의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Sonos에 대한 시장 심리를 평가합니다..

Sonos (NASDAQ:SONO) 주식, 옵션 체인

Sonos

Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa and the Asia Pacific. Generating a majority of its revenue from the Americas.

Earnings

News

After-Hours Center

Movers

SONO

소노스(NASDAQ:SONO)는 수요일(13일) 장 마감 후 4분기 실적을 발표했다. 이번 분기 실적 주요 수치는 다음과 같다.실적 세부 내용: 소노스의 GAAP 분기 주당순손실은 44센트로 애널리스트 컨센서스 예상치 주당순손실 38센트에 미치지 못했다. 분기 매출은 2억 5,540만 달러로 애널리스트 컨센서스 예상치 2억 4,949만 달러를 상회했다. 소노스의 분기 GAAP 매출총이익률은 40.3%를 기록했다.

소노스, 엇갈린 4분기 실적 발표 후 시간외 거래 5% 상승

Sonos Inc

SONO GROUP N V by Sono Group N.V.

Sono Group NV

Sono-Tek Corp

Sonoco Products Co

Sonocom Co Ltd

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals Inc

SONOMAX TECHNOLOGIES INC by Sonomax Technologies Inc

Sonomax Technologies Inc

Sonoran Desert Copper Corp

SONORAN DESERT COPPER CP by SONORAN DESERT COPPER CORP

Sonoro Energy Ltd

Sonoro Gold Corp

SONOVA HOLDING AG ORD by Sonova Holding AG

Sonova Holding AG

SONOVA HLDNG AG UNSP/ADR by Sonova Holding AG

Sonovia Ltd

Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) has been analyzed by 25 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Nike and provided 12-month price targets. The average target is $83.44, accompanied by a high estimate of $105.00 and a low estimate of $70.00. Observing a downward trend, the current average is 4.0% lower than the prior average price target of $86.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1736514153_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Nike among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$75.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Joseph Civello</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$74.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$80.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$97.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$93.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$79.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$84.00</td>
<td>-</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$73.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Piral Dadhania</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nike. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nike compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Nike's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Nike's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NKE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nike analyst ratings.</a>
<h2>Unveiling the Story Behind Nike</h2>
Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.
<h3>Financial Milestones: Nike's Journey</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Nike showcased positive performance, achieving a revenue growth rate of 6.6% as of 30 November, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.41%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Nike's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.31% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Nike's ROA stands out, surpassing industry averages. With an impressive ROA of 3.07%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Nike's debt-to-equity ratio is below the industry average at 0.86, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Nike: 25 Analysts Share Their Views

Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $37.5, a high estimate of $40.00, and a low estimate of $34.00. This current average has increased by 4.17% from the previous average price target of $36.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1736514129_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Verint Systems among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$34.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Dan Bergstrom</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Verint Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Verint Systems compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Verint Systems's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Verint Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VRNT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Verint Systems analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Verint Systems's Background</h2>
Verint Systems Inc with its subsidiaries helps brands provide Boundless Customer Engagement. The company's solutions help iconic brands close the gap created when it lacks the resources required to deliver experiences that fulfill customer expectations. Geographically, it derives a majority of its revenue from the United States.
<h3>A Deep Dive into Verint Systems's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3 months period, Verint Systems showcased positive performance, achieving a revenue growth rate of 2.58% as of 31 October, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 11.02%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Verint Systems's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.88%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Verint Systems's ROA stands out, surpassing industry averages. With an impressive ROA of 1.12%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Verint Systems's debt-to-equity ratio is below the industry average at 0.5, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRNT

Assessing Verint Systems: Insights From 4 Financial Analysts

~ Horizon Aircraft Will Deliver 5 Cavorite X7s in 2028 ~
~ The Cavorite X7 Provides a Cost-Effective Alternative to Traditional Helicopters with Twice the Speed and up 75% Lower Operating Costs ~
TORONTO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- New Horizon Aircraft Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>), doing business as Horizon Aircraft ("Horizon Aircraft" or the "Company"), a leading hybrid electric Vertical Take-Off and Landing ("eVTOL") aircraft developer, announced today it has signed a Letter of Intent ("LOI") with Discovery Air Chile Ltda., a leading Chilean helicopter operator to lease five Cavorite X7 eVTOLs with a projected delivery timeline of 2028. The addition of this unique eVTOL aircraft will transform services in Chile by dramatically reducing transfer times for passengers, patients, and time sensitive goods while cutting costs for operators.

Contracts

HOVR

Horizon Aircraft Signs LOI With Discovery Air Chile Ltda. To Lease Five Cavorite X7 eVTOLs With A Projected Delivery Timeline Of 2028

Deutsche Bank analyst Omotayo Okusanya upgrades National Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSA#NYSE">NSA</a>) from Sell to Hold and lowers the price target from $40 to $38.

Upgrades

Price Target

Deutsche Bank Upgrades National Storage to Hold, Lowers Price Target to $38

Throughout the last three months, 11 analysts have evaluated ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $82.45, a high estimate of $100.00, and a low estimate of $60.00. Observing a downward trend, the current average is 2.23% lower than the prior average price target of $84.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1736514092_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of ON Semiconductor by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$60.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Suji Desilva</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$87.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$89.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$64.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$92.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ON Semiconductor. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of ON Semiconductor compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of ON Semiconductor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into ON Semiconductor's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ON/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ON Semiconductor analyst ratings.</a>
<h2>Discovering ON Semiconductor: A Closer Look</h2>
Onsemi is a supplier of power semiconductors and sensors focused on the automotive and industrial markets. Onsemi is the second-largest power chipmaker in the world and the largest supplier of image sensors to the automotive market. While the firm used to be highly vertically integrated, it now pursues a hybrid manufacturing strategy for flexible capacity. Onsemi is pivoting to focus on emerging applications like electric vehicles, autonomous vehicles, industrial automation, and renewable energy.
<h3>Key Indicators: ON Semiconductor's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: ON Semiconductor's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -19.21%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: ON Semiconductor's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 22.8% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): ON Semiconductor's ROE excels beyond industry benchmarks, reaching 4.75%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ON Semiconductor's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.91%, the company showcases efficient use of assets and strong financial health.
Debt Management: ON Semiconductor's debt-to-equity ratio is below the industry average at 0.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On ON Semiconductor Through 11 Analysts

In the latest quarter, 5 analysts provided ratings for ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $256.6, a high estimate of $283.00, and a low estimate of $232.00. This upward trend is evident, with the current average reflecting a 1.96% increase from the previous average price target of $251.67.
<img src="https://www.benzinga.com/files/images/story/2025/1736514077_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of ResMed by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$252.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Announces</td>
<td>Hold</td>
<td>$250.00</td>
<td>-</td>
</tr>
<tr>
<td>Craig Wong-Pan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$232.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$266.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$283.00</td>
<td>$280.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ResMed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ResMed compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of ResMed's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RMD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ResMed analyst ratings.</a>
<h2>About ResMed</h2>
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
<h3>ResMed: Delving into Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: ResMed's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 11.08%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 25.43%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): ResMed's ROA excels beyond industry benchmarks, reaching 4.42%. This signifies efficient management of assets and strong financial health.
Debt Management: ResMed's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.16.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 5 Analyst Ratings Have To Say About ResMed

Across the recent three months, 10 analysts have shared their insights on Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $37.4, a high estimate of $44.00, and a low estimate of $30.00. Experiencing a 2.35% decline, the current average is now lower than the previous average price target of $38.30. 
<img src="https://www.benzinga.com/files/images/story/2025/1736514040_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Warner Music Gr by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Batya Levi</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Vijay Jayant</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Jason Bazinet</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$34.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Alan Gould</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$35.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>David Karnovsky</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Kannan Venkateshwar</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Warner Music Gr. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Warner Music Gr compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Warner Music Gr's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Warner Music Gr's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WMG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Warner Music Gr analyst ratings.</a>
<h2>All You Need to Know About Warner Music Gr</h2>
Warner Music is the third-largest of the three major record companies. Recorded music accounts for most of the firm's revenue, with the segment housing notable record labels including Atlantic Records, Warner Records, Elektra Records. Some of the most successful current artists signed to record deals with Warner include Ed Sheeran, Bruno Mars, Cardi B, and Dua Lipa. Warner's remaining revenue comes from its publishing business, where Warner Chappell represents more than 180,000 songwriters and composers, some of whom are also Warner recording artists but many of whom are not recording artists or are attached to other labels. Warner Chappel controls more than 1 million musical compositions. Access Industries controls 98% of Warner's voting rights, while holding a 72% economic interest.
<h3>Financial Insights: Warner Music Gr</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Warner Music Gr showcased positive performance, achieving a revenue growth rate of 2.77% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: Warner Music Gr's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.52%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Warner Music Gr's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 8.19%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.46%, the company showcases effective utilization of assets.
Debt Management: Warner Music Gr's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 8.28.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Have This To Say About Warner Music Gr

8 analysts have shared their evaluations of Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $67.38, with a high estimate of $78.00 and a low estimate of $60.00. This upward trend is evident, with the current average reflecting a 8.38% increase from the previous average price target of $62.17.
<img src="https://www.benzinga.com/files/images/story/2025/1736514025_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Avidity Biosciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$72.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$67.00</td>
<td>-</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$56.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Avidity Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Avidity Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Avidity Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Avidity Biosciences's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Avidity Biosciences analyst ratings.</a>
<h2>Discovering Avidity Biosciences: A Closer Look</h2>
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
<h3>Financial Insights: Avidity Biosciences</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Avidity Biosciences's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -17.1% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -3441.7%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Avidity Biosciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.9%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Avidity Biosciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -5.38%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Avidity Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Avidity Biosciences's Future

BlackRock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>), the world&#8217;s largest asset manager with $11.5 trillion in assets, has withdrawn from the Net Zero Asset Managers initiative, a global group committed to achieving net zero greenhouse gas emissions by 2050 or sooner, following President-elect Donald Trump&#8216;s victory and increasing regulatory pressure.
In a letter to institutional clients, Vice-Chair Philipp Hildebrand cited regulatory inquiries and client confusion as key factors driving the decision, the Financial Times <a href="https://www.ft.com/content/f0fb9841-db1d-442e-a757-1a1327497fb1">reported</a> on Thursday. 
The move follows similar <a href="https://www.benzinga.com/government/regulations/25/01/42770035/bank-of-america-citigroup-exit-climate-alliance-as-trump-policies-shift-energy-priorities">exits by major U.S. banks, </a>including JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) and Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), from climate alliances.
BlackRock&#8217;s environmental proxy voting support has declined significantly, dropping from 47% in 2021 to 4% last year, reflecting a broader shift in its climate stance. The firm maintains this decision won&#8217;t alter its approach to climate risk assessment in portfolio management, even as it faces ongoing litigation from 11 Republican-led states regarding its environmental policies.
Meanwhile, the Trump administration aims to <a href="https://www.benzinga.com/markets/commodities/24/11/42235640/trumps-energy-policies-poised-to-reshape-oil-gas-market-winners-and-losers-revealed">boost energy production by 3 million barrels </a>of oil equivalent per day, introduce a potential 25% tariff on Canadian oil and gas imports, and expedite the approval process for liquefied natural gas (LNG) exports.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42904377/tesla-bull-gary-black-warns-against-inflated-optimus-robot-assumptions-get-pounded-each-time-i-try-to-right-size-expectations">Tesla Bull Gary Black Warns Against Inflated Optimus Robot Assumptions: Get Pounded Each Time &#8216;I Try To Right-Size Expectations&#8217;</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Markets

Trump Fallout? BlackRock Exits Climate Alliance, Cites Regulatory Pressure And Client Confusion

Deutsche Bank analyst Omotayo Okusanya upgrades CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) from Sell to Hold and lowers the price target from $46 to $45.

CUBE

Deutsche Bank Upgrades CubeSmart to Hold, Lowers Price Target to $45

D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) with a Buy and maintains $9 price target.

IVVD

D. Boral Capital Maintains Buy on Invivyd, Maintains $9 Price Target

JFBR

Jeffs' Brands Estimates Its Revenues For The Year Ended December 31, 2024 To Exceed $13M, Reflecting An Approximately 30% YoY Growth; Anticipates over 120% Revenue Growth Since Its IPO In 2022

American Electric Power Company Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) shares are trading higher in premarket Friday.
The company announced that a 50/50 strategic partnership between KKR &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) and PSP Investments has agreed to acquire&nbsp;19.9%&nbsp;non-controlling equity interest in its Ohio&nbsp;and&nbsp;Indiana&nbsp;&amp; Michigan Transmission Companies <a target="_blank" href="https://www.benzinga.com//node/42901587" rel="noreferrer noopener">(Transcos)&nbsp;for&nbsp;$2.82 billion.</a>
The deal is expected to boost AEP&#8217;s ability to finance its $54 billion capital investment plan over the next five years.
The partnership will also allow AEP to improve the reliability of its transmission infrastructure and strengthen its balance sheet, to meet growing customer demand in the Midwest.
The stake acquired represents roughly 5% of AEP&#8217;s overall transmission rate base. The capital raised through this transaction will fund key projects across transmission, distribution, and generation, helping AEP manage its equity financing requirements through 2029.
&#8220;Executing on our five-year capital plan is critical to meeting growing energy demand and bolstering reliability for our customers. Electricity demand is anticipated to grow significantly in AEP&#8217;s footprint by the end of the decade,&#8221; said&nbsp;Bill Fehrman,&#8221; said AEP President and CEO Bill Fehrman.
&#8220;KKR and PSP Investments are experienced investors in the utilities and energy space with a proven track record of successful infrastructure investments.&#8221;
The transaction is expected to be completed in the second half of 2025 and is said to immediately benefit AEP&#8217;s earnings.
The agreement requires approval from FERC and clearance from the Committee on Foreign Investment in&nbsp;the U.S.
Price Action: AEP shares are trading higher by 0.81% at $93.01 in premarket at the last check Friday.
Photo via Shutterstock.

Asset Sales

General

American Electric Power Sells 19.9% Stake In Two Transmission Assets For $2.82B: Details

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Buy and maintains $128 price target.

BMEA

D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $128 Price Target

ESSA

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

Northland Capital Markets analyst Ted Jackson maintains Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) with a Outperform and raises the price target from $4 to $10.

AMPX

Northland Capital Markets Maintains Outperform on Amprius Technologies, Raises Price Target to $10

Guidance

ETWO

E2open Trims FY25 Revenue Outlook To $607M - $611M From $607M - $617M

Northland Capital Markets analyst Mike Grondahl maintains Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Outperform and raises the price target from $20 to $24.

BTDR

Northland Capital Markets Maintains Outperform on Bitdeer Technologies, Raises Price Target to $24

Wells Fargo analyst Ike Boruchow downgrades Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) from Overweight to Equal-Weight and maintains the price target from $165 to $165.

Downgrades

ROST

Wells Fargo Downgrades Ross Stores to Equal-Weight, Maintains Price Target to $165

Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) co-founder Joe Lonsdale offered a sobering assessment of the Department of Government Efficiency initiative, suggesting that while $1 trillion in federal spending cuts might be achievable, further reductions would face significant hurdles.
What Happened: &#8220;The next trillion will be a lot harder,&#8221; Lonsdale said during a CNBC <a href="https://www.youtube.com/watch?v=RBAGWBQNogU">interview</a> on Thursday, tempering expectations for the ambitious cost-cutting program championed by Tesla Inc. CEO Elon Musk. The initiative, which initially targeted $2 trillion in cuts, has recently scaled back its goals.
Lonsdale revealed that the effort has attracted significant talent, noting, &#8220;I know dozens of friends who are helping out in various ways—brilliant engineers and lawyers working day and night.&#8221; However, he emphasized that government resistance and bureaucratic obstacles would make deeper cuts challenging.
The discussion gains particular significance as President-elect Donald Trump&#8216;s team plans to integrate DOGE into a second administration. 
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/42904377/tesla-bull-gary-black-warns-against-inflated-optimus-robot-assumptions-get-pounded-each-time-i-try-to-right-size-expectations">Tesla Bull Gary Black Warns Against Inflated Optimus Robot Assumptions: Get Pounded Each Time &#8216;I Try To Right-Size Expectations&#8217;</a>
Why It Matters: Lonsdale, who <a href="https://www.benzinga.com/markets/equities/24/09/40786654/elon-musk-invites-joe-lonsdale-to-join-d-o-g-e-but-palantir-founder-points-out-failure-of-simila">previously attempted similar efficiency initiatives</a> during the former President Barack Obama&#8216;s administration, shared a cautionary tale: &#8220;Obama even verbally agreed to let us do it back in the day but then his people stopped it from going ahead; wasn&#8217;t politically useful to find all that for some reason.&#8221;
Analyzing potential savings areas, Lonsdale identified fraud reduction, entitlement reform, and elimination of unused government buildings as promising targets. However, he expressed skepticism about substantial defense spending cuts, citing strong bipartisan support in Congressional committees and national security considerations.
The initiative&#8217;s evolution reflects growing attention to government efficiency as Trump has appointed Musk to lead a commission auditing federal agencies. This alignment of technology leaders with government reform efforts marks a significant shift in approaches to <a href="https://www.benzinga.com/news/global/24/11/41927289/trump-appoints-elon-musk-and-vivek-ramaswamy-to-lead-doge-targeting-bureaucracy-and-65-trillion-federal-spending-we-will-not-go-gently">federal spending reduction</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42906328/crypto-fear-and-greed-index-hits-lowest-level-since-october-as-bitcoin-falls-under-92k-dogecoin-and-shiba-inu-trade-in-red">Crypto Fear And Greed Index Hits Lowest Level Since October As Bitcoin Falls Under $92K, Dogecoin And Shiba Inu Trade In Red</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Government

Global

PLTR

TSLA

Palantir Co-Founder Joe Lonsdale Sets Realistic Expectations For Elon Musk's DOGE Initiative: 'Next Trillion Will Be A Lot Harder'

Sonos, Inc. 2024 Q4 - Results - Earnings Call Presentation

Sonos, Inc. (SONO) Q4 2024 Earnings Call Transcript

Sees Q1 adjusted EBITDA $35M-$79M. Sees Q1 GAAP gross margin 41%-43%. Guidance taken from Q4 earnings conference call. Published first on TheFly – ...

Sonos sees Q1 revenue $480M-$560M, consensus $518.95M

Craig-Hallum analyst Alex Fuhrman raised the firm's price target on Sonos (SONO) to $15 from $10 and keeps a Hold rating on the shares. The firm no...

Sonos price target raised to $15 from $10 at Craig-Hallum

Audio manufacturer Sonos Inc. ($SONO) posted mixed results for Q4 2024. The company has experienced a challenging environment owing to an unprecede...

Sonos' (SONO) Rebounding from Mobile App Debacle

Sonos Inc (SONO) has disclosed a new risk, in the Demand category. Sonos Inc. is facing significant challenges following the launch of its redesign...

Sonos Faces Financial Strain Amid App Rollout Challenges

Trade Desk working on TV OS 'Ventura,' CEO says efforts won't compete with Roku - report

Catalyst Watch: Robotaxi IPO, OPEC+, holiday shopping data, and movie blockbusters

Sonos: This Turnaround Will Take Awhile (Rating Downgrade)

American Century Small Cap Growth Fund Q3 2024 Commentary

ADMA

AMZN

AVDX

AZEK

BBWI

BOOT

CGJTF

CMCSA

CRWD

CWST

DELL

ENVX

ETSY

FBIN

GOOG

GOOGL

HEAR

HNST

IBRX

ITGR

JNPR

MSTR

NTGR

NTRA

OLLI

PARA

PENN

PONY

QTWO

REGN

ROKU

SITE

SPOT

TRUE

TTGT

VSTO

WDAY

XPRO

ZNOG

Press Releases

Sonos Announces Participation in Maxim Group Virtual Tech Conference

Sonos Announces Date for Third Quarter Fiscal 2024 Financial Results and Conference Call

Sonos Reports Third Quarter Fiscal 2024 Results

Sonos and Sporty & Rich Serve Up Tenniscore Style with New Limited Edition Headphones

Sonos Announces New Quality and Customer Experience Commitments

Sonos Reveals Arc Ultra, its New Soundbar Featuring Sound Motion™

Sonos Announces Date for Fourth Quarter and Fiscal 2024 Financial Results and Conference Call

Sonos Reports Fourth Quarter and Fiscal 2024 Results

Sonos to Launch Era 100 Pro, Its First-Ever Solution for Professional Installation, in January 2025

Sonos Reports Environmental Progress On Headphones, New Products, and Climate Plan

Comments

Sonos

Sonos (SONO) 옵션

Sonos (NASDAQ:SONO) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌